Release Date: 13-Jul-2024
In late April 2024, ImmunityBio unveiled a groundbreaking advancement in the field of oncology with the FDA’s approval of Anktiva plus Bacillus Calmette-Guandeacute;rin (BCG) for the treatment of patients grappling with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. This milestone marks the dawn of a new era in immunotherapy, transcending the realms of checkpoint inhibitors to usher in a novel approach towards combating bladder cancer. Anktiva stands as a first-in-class IL-15 agonist immunotherapy, offering renewed hope to patients confronting the formidable challenge of NMIBC.
By stimulating the proliferation and activation of natural killer (NK) cells and CD8+ killer T cells, Anktiva induces a multifaceted immune response within the patient’s body. Additionally, it activates CD4+ T helper cells, which further bolster the expansion of memory killer T cells. This innovative mechanism mirrors the biological functions of dendritic cells, marking a significant advancement in immunotherapy beyond conventional T cell-focused approaches. By promoting the proliferation of crucial anti-cancer immune cells and activating memory T cells, Anktiva fosters durable complete responses, paving the way for enhanced efficacy in cancer treatment.
Anktiva represents a pioneering combination product comprising Nogapendekin alfa, a human IL-15N72D variant, and Inbakicept, an IL-15 receptor agonist. This synergistic blend harnesses the power of IL-15 to stimulate the activation and proliferation of natural killer cells and CD8+ memory T cells, thereby enhancing the efficacy of BCG therapy. By leveraging the intricate interplay between the immune system and tumor microenvironment, Anktiva redefines the treatment landscape for BCG-unresponsive NMIBC.
The FDA’s approval of Anktiva is underpinned by compelling evidence derived from the Phase 2/3 QUILT-3.032 trial, a seminal study that evaluated the safety and efficacy of this innovative immunotherapy in 77 patients with BCG-unresponsive, high-risk NMIBC with CIS, with or without Ta/T1 papillary disease. Patients underwent induction therapy via intravesical instillation with Anktiva in conjunction with BCG, followed by maintenance therapy spanning up to 37 months.
The trial yielded promising outcomes, with a remarkable complete response (CR) rate of 62% observed among evaluable patients. Furthermore, the duration of complete response, as of the November 2023 cut-off, exceeded 47 months and continues to persist. These prolonged response durations surpass the benchmarks established by the International Bladder Cancer Group (IBCG) for meaningful clinical results beyond 24 months, underscoring the transformative potential of Anktiva in achieving durable remissions.
Amidst the efficacy achievements, Anktiva demonstrated a manageable safety profile, with the most common adverse reactions including laboratory test abnormalities such as increased creatinine, as well as urinary symptoms like dysuria, hematuria, and urinary frequency. Musculoskeletal pain, chills, and pyrexia were also reported, albeit at lower frequencies.
Anktiva previously earned the Breakthrough Therapy Designation, a testament to its remarkable potential, driven by compelling results from its clinical trial. This designation underscores the urgency and significance of Anktiva’s development in addressing unmet medical needs in cancer therapy.
With its approval, Anktiva heralds a paradigm shift in the management of NMIBC, offering a beacon of hope to patients and clinicians alike. By surpassing established benchmarks for durable complete response, Anktiva has the potential to redefine the standard of care for BCG-unresponsive bladder cancer. Moreover, its novel mechanism of action underscores the transformative potential of immunotherapy in reshaping the treatment landscape and elevating patient outcomes.
In conclusion, the FDA approval of Anktiva marks a watershed moment in the field of oncology, particularly in the management of BCG-unresponsive NMIBC. With its unparalleled efficacy and manageable safety profile, Anktiva epitomizes the convergence of scientific innovation and clinical excellence. As we embark on this transformative journey, Anktiva holds the promise of revolutionizing bladder cancer treatment and offering renewed hope to patients facing this formidable disease.
For Clinical Trials Information Contact